These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

949 related items for PubMed ID: 14586719

  • 1. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
    Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K.
    Hypertens Res; 2009 Apr; 32(4):270-5. PubMed ID: 19262495
    [Abstract] [Full Text] [Related]

  • 3. Prospective and randomized study of the antihypertensive effect and tolerability of three antihypertensive agents, losartan, amlodipine, and lisinopril, in hypertensive patients.
    Wu SC, Liu CP, Chiang HT, Lin SL.
    Heart Vessels; 2004 Jan; 19(1):13-8. PubMed ID: 14685749
    [Abstract] [Full Text] [Related]

  • 4. [Pharmacogenetics of angiotensin system in non diabetic nephropathy].
    Coto E, Marín R, Alvarez V, Praga M, Fernández Andrade C, Arias M, Poveda R, Vallés M, Galcerán JM, Luño J, Rivera F, Campistol JM.
    Nefrologia; 2005 Jan; 25(4):381-6. PubMed ID: 16231503
    [Abstract] [Full Text] [Related]

  • 5. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study.
    Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchii Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.
    Hypertens Res; 2004 Jan; 27(1):21-30. PubMed ID: 15055252
    [Abstract] [Full Text] [Related]

  • 6. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group.
    Wilson TW, Lacourcière Y, Barnes CC.
    CMAJ; 1998 Sep 08; 159(5):469-76. PubMed ID: 9757170
    [Abstract] [Full Text] [Related]

  • 7. The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension.
    Watanabe S, Okura T, Kurata M, Irita J, Manabe S, Miyoshi K, Fukuoka T, Murakami K, Higaki J.
    Clin Ther; 2006 Oct 08; 28(10):1677-85. PubMed ID: 17157123
    [Abstract] [Full Text] [Related]

  • 8. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria.
    Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE.
    J Pediatr; 2003 Jul 08; 143(1):89-97. PubMed ID: 12915830
    [Abstract] [Full Text] [Related]

  • 9. Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease.
    Abe M, Okada K, Maruyama T, Matsumoto K.
    Pharmacotherapy; 2009 Sep 08; 29(9):1061-72. PubMed ID: 19698011
    [Abstract] [Full Text] [Related]

  • 10. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
    Agarwal R, Siva S, Dunn SR, Sharma K.
    Am J Kidney Dis; 2002 Mar 08; 39(3):486-92. PubMed ID: 11877567
    [Abstract] [Full Text] [Related]

  • 11. Treatment of hypertension in chronic kidney disease.
    Toto RD.
    Semin Nephrol; 2005 Nov 08; 25(6):435-9. PubMed ID: 16298269
    [Abstract] [Full Text] [Related]

  • 12. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
    Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T.
    Hypertens Res; 2007 Sep 08; 30(9):797-806. PubMed ID: 18037772
    [Abstract] [Full Text] [Related]

  • 13. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.
    Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H.
    Hypertens Res; 2007 Jul 08; 30(7):621-6. PubMed ID: 17785930
    [Abstract] [Full Text] [Related]

  • 14. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM, RENAAL Study Group.
    Arch Intern Med; 2003 Jul 14; 163(13):1555-65. PubMed ID: 12860578
    [Abstract] [Full Text] [Related]

  • 15. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal failure (AVER) Study Group.
    Clin Ther; 2008 Mar 14; 30(3):482-98. PubMed ID: 18405787
    [Abstract] [Full Text] [Related]

  • 16. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
    Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, Hosoya T, Nakayama T, Yamamoto N, Higaki Y, Shimizu T.
    Nephron Clin Pract; 2005 Mar 14; 99(1):c18-23. PubMed ID: 15637459
    [Abstract] [Full Text] [Related]

  • 17. Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
    Miyagawa K, Dohi Y, Nakazawa A, Sugiura T, Yamashita S, Sato K, Kimura G.
    Clin Exp Hypertens; 2010 Jan 14; 32(1):1-7. PubMed ID: 20144066
    [Abstract] [Full Text] [Related]

  • 18. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.
    Arch Intern Med; 2005 Apr 25; 165(8):936-46. PubMed ID: 15851647
    [Abstract] [Full Text] [Related]

  • 19. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease.
    Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE.
    J Hypertens Suppl; 1994 Jul 25; 12(2):S37-42. PubMed ID: 7965264
    [Abstract] [Full Text] [Related]

  • 20. Hemodynamic and 24-h blood pressure profile of amlodipine monotherapy.
    Ibrahim MM, el-Boghdadly B, Zaghloul SS.
    J Hum Hypertens; 1996 Jul 25; 10(7):489-94. PubMed ID: 8880565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.